{"id":4012,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/fosamprenavir-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"fosamprenavir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/fosamprenavir-txt\/","title":{"rendered":"Fosamprenavir.txt"},"content":{"rendered":"

Fosamprenavir <\/h1>\n

CLINICAL USE <\/H3>
\nProtease inhibitor:For HIV infection, in combination with other antiretroviral drugs

DOSE IN NORMAL RENAL FUNCTION <\/H3>700 mg twice daily with ritonavir 100 mg twice daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :625.7 (as calcium salt)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :90 (amprenavir)<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <1 (amprenavir)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :6 (amprenavir)<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :7.7\/Unchanged (amprenavir)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: possibly increased concentration of amiodarone, flecainide, lidocaine and propafenone (increased risk of ventricular arrhythmias) \u2013 avoid concomitant use\n
  • Antibacterials: concentration of both drugs increased with erythromycin; increases concentration of rifabutin \u2013 reduce rifabutin dose; concentration significantly reduced by rifampicin \u2013 avoid concomitant use; possibly increases dapsone concentration; avoid concomitant use with telithromycin in severe renal and hepatic impairment\n
  • Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid concomitant use; possibly increases side effects of tricyclics; possibly reduces paroxetine concentration\n
  • Antimalarials: avoid concomitant administration with artemether\/lumefantrine\n
  • Antipsychotics: possibly inhibits aripiprazole metabolism \u2013 reduce aripiprazole dose; possibly increases clozapine concentration; possibly increases pimozide and sertindole concentration (increased risk of ventricular arrhythmias) \u2013 avoid concomitant use\n
  • Antivirals: concentration reduced by efavirenz, lopinavir and tipranavir; concentration possibly reduced by nevirapine; concentration increased by ritonavirAnxiolytics and hypnotics: increased risk of prolonged sedation and respiratory depression with alprazolam, clonazepam, diazepam, flurazepam and midazolamCilostazol: possibly increases cilostazol concentration \u2013 avoid concomitant use\n
  • Ergot alkaloids: increased risk of ergotism \u2013 avoid concomitant useImmunosuppressants: monitor ciclosporin, tacrolimus and sirolimus levelsStatins: possibly increased risk of myopathy with atorvastatin; possibly increased myopathy with simvastatin \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Prodrug of amprenavir, 700 mg of fosamprenavir is equivalent to 600 mg amprenavir.
    \n","protected":false},"excerpt":{"rendered":"

    Fosamprenavir CLINICAL USE Protease inhibitor:For HIV infection, in combination with<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4012","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4012"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4012\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}